1. Bivalent vaccines that confer protection against rabies and other viruses We have been developing a rabies virus based vaccine that expresses the glycoprotein (GP) from ebolavirus, marburgvirus and sudanvirus, the GPC from lassa virus, and the Spike protein from MERS-CoV. Previously we developed (a) replication-competent, (b) replication-deficient, and (c) chemically inactivated rabies virus (RABV) vaccines expressing Zaire ebolavirus (EBOV) glycoprotein (GP) using a reverse genetics system based on the SAD B19 RABV wildlife vaccine in collaboration with Matthias Schnell of Thomas Jefferson University. Immunization with live or inactivated RABV vaccines expressing EBOV GP induced cellular and humoral immunity against each virus and conferred protection from both lethal RABV and EBOV challenge in mice. We have continued our evaluation of the RABV based EBOV vaccine and have found that an adjuvant improves efficacy of the inactivated vaccine in rhesus and cynomolgus macaque challenge models. A clinical trial lot of the rabies-ebolavirus has been produced and evaluated in NHPs. The Marburg-rabies construct has demonstrated immunogenicity in mice and efficacy testing in mice is underway. If successful, then efficacy testing in nonhuman primate models of Marburg virus will be pursued. The RABV-MERS vaccine has demonstrated immunogenicity and efficacy in mice. A study in camels is currently being planned. The RABV-Lassa virus vaccine candidate has demonstrated immunogenicity in mice. Safety and efficacy testing in mice and guinea pigs is scheduled to start in fall of 2016. If successful, then efficacy will be evaluated in NHP models. 2. Animal model development. EVPS is currently developing PET/CT to investigate pathogenesis of EBOV infection in NHPs. We have evaluated 18-fluorodeoxyglucose as a marker of increased glucose metabolism as a marker of inflammation and 18-fluoro-Albumin as a hemodynamic marker. We observed increased metabolism in the spleen, liver, bone marrow and draining lymph nodes that progressed rapidly and plateaued 5 days post-infection and rapidly decreased as subjects met endpoint criteria. 18-fluoro-Albumin imaging indicated congestion in the bone marrow and spleen. These data indicate that PET/CT imaging can be used to evaluate disease progression in real-time, thus establishing biomarkers that can be used to validate potential countermeasures and increase understanding of pathogenesis. 3.Filovirus Molecular Virology We have resolved the secondary structure of the EBOV 3E-5E minigenome by selective hydroxyl acylation by primer extension. Previously, we identified host proteins that interact with the EBOV trailer. Specifically, HSPA8 binds to a specific motif within the EBOV trailer and mutational analysis, chemical inhibition targeting HSPA8, and reverse genetics have demonstrated a role for HSPA8 in the virus lifecycle. We are currently identifying host proteins that interact with the EBOV NCRs from cell lines of varying permissivity to EBOV infection. Based on these data we may identify therapeutic targets as well as establish mechanisms of filovirus lifecycle regulation.

Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
Zip Code
Cockrell, Adam S; Johnson, Joshua C; Moore, Ian N et al. (2018) A spike-modified Middle East respiratory syndrome coronavirus (MERS-CoV) infectious clone elicits mild respiratory disease in infected rhesus macaques. Sci Rep 8:10727
Perry, Donna L; Huzella, Louis M; Bernbaum, John G et al. (2018) Ebola Virus Localization in the Macaque Reproductive Tract during Acute Ebola Virus Disease. Am J Pathol 188:550-558
DeWald, Lisa Evans; Dyall, Julie; Sword, Jennifer M et al. (2018) The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease. J Infect Dis :
Cornish, Joseph P; Diaz, Larissa; Ricklefs, Stacy M et al. (2017) Sequence of Reston Virus Isolate AZ-1435, an Ebolavirus Isolate Obtained during the 1989-1990 Reston Virus Epizootic in the United States. Genome Announc 5:
Dyall, Julie; Gross, Robin; Kindrachuk, Jason et al. (2017) Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. Drugs 77:1935-1966
Wirblich, Christoph; Coleman, Christopher M; Kurup, Drishya et al. (2017) One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus. J Virol 91:
Keshwara, Rohan; Johnson, Reed F; Schnell, Matthias J (2017) Toward an Effective Ebola Virus Vaccine. Annu Rev Med 68:371-386
Sztuba-Solinska, Joanna; Diaz, Larissa; Kumar, Mia R et al. (2016) A small stem-loop structure of the Ebola virus trailer is essential for replication and interacts with heat-shock protein A8. Nucleic Acids Res 44:9831-9846
Luke, Thomas; Wu, Hua; Zhao, Jincun et al. (2016) Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med 8:326ra21
Johnson, Reed F; Kurup, Drishya; Hagen, Katie R et al. (2016) An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models. J Infect Dis 214:S342-S354

Showing the most recent 10 out of 70 publications